UBX Unity Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: UBX

Price (delayed)

$1.61

Market cap

$27.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.7

Enterprise value

$30.76M

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells ...

Highlights
UBX's debt has dropped by 50% year-on-year and by 3.7% since the previous quarter
The quick ratio has grown by 14% YoY and by 3.6% from the previous quarter
The EPS has dropped by 72% since the previous quarter but it is up by 42% year-on-year
UBX's net income is up by 10% YoY but it is down by 8% from the previous quarter
UBX's gross profit has dropped by 100% year-on-year
The revenue has plunged by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://unitybiotechnology.com
Peers: OMER OMGA

Key stats

What are the main financial stats of UBX
Market
Shares outstanding
16.79M
Market cap
$27.03M
Enterprise value
$30.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$37.41M
EBITDA
-$36.23M
Free cash flow
-$36.98M
Per share
EPS
-$2.7
Free cash flow per share
-$2.5
Book value per share
$1.94
Revenue per share
$0
TBVPS
$4.45
Balance sheet
Total assets
$65.69M
Total liabilities
$37.29M
Debt
$23.54M
Equity
$28.4M
Working capital
$38.77M
Liquidity
Debt to equity
0.83
Current ratio
5.94
Quick ratio
5.51
Net debt/EBITDA
-0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-45.5%
Return on equity
-92.4%
Return on invested capital
-41.8%
Return on capital employed
-64.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UBX stock price

How has the Unity Biotechnology stock price performed over time
Intraday
-1.23%
1 week
7.33%
1 month
1.9%
1 year
-30.3%
YTD
-16.58%
QTD
-1.83%

Financial performance

How have Unity Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.67M
Net income
-$39.86M
Gross margin
N/A
Net margin
N/A
UBX's gross profit has dropped by 100% year-on-year
The revenue has plunged by 100% YoY
UBX's operating income is up by 22% year-on-year and by 13% since the previous quarter
UBX's net income is up by 10% YoY but it is down by 8% from the previous quarter

Growth

What is Unity Biotechnology's growth rate over time

Valuation

What is Unity Biotechnology stock price valuation
P/E
N/A
P/B
0.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 72% since the previous quarter but it is up by 42% year-on-year
The P/B is 59% less than the 5-year quarterly average of 2.0 but 3.8% more than the last 4 quarters average of 0.8
UBX's equity is down by 49% year-on-year and by 22% since the previous quarter
The revenue has plunged by 100% YoY

Efficiency

How efficient is Unity Biotechnology business performance
UBX's ROIC is down by 35% since the previous quarter and by 33% year-on-year
UBX's return on equity is down by 25% since the previous quarter and by 17% year-on-year
UBX's ROA is down by 25% since the previous quarter and by 20% year-on-year

Dividends

What is UBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UBX.

Financial health

How did Unity Biotechnology financials performed over time
UBX's total assets is 76% greater than its total liabilities
UBX's total assets is down by 47% year-on-year and by 5% since the previous quarter
Unity Biotechnology's total liabilities has decreased by 45% YoY but it has increased by 13% QoQ
UBX's debt is 17% smaller than its equity
UBX's debt has dropped by 50% year-on-year and by 3.7% since the previous quarter
UBX's equity is down by 49% year-on-year and by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.